Author: Christophe Pinto (Portugal)
Co-authors: Keissy Sousa, Eliana Oliveira, Luís Mendonça, Rita Gentil, Lara Queirós, Manuel Falcão
Purpose
During the last decade, verteporfin half-dose photodynamic therapy (HD-PDT) has been demonstrated to maintain efficacy when treating acute or chronic Central Serous Chorioretinopathy (cCSC) while reducing the risk of sight-threatening complications. In general, reduced-setting PDT can be broadly applied to treat subfoveal, juxtafoveal and extrafoveal leakage points, whereas a safety distance to the fovea has been traditionally imposed for conventional laser and high-density subthreshold micropulse laser to avoid central vision damage. This study aims to compare the efficacy and safety of foveal and extrafoveal HD-PDT for cCSC.
Setting/Venue
Department of Ophthalmology, Hospital de Braga, Braga, Portugal.
Methods
This retrospective, cohort study included cCSC eyes submitted to HD-PDT on foveal (F) or extrafoveal (E) areas. Patients were evaluated at baseline and 12 weeks after treatment for best corrected visual acuity (BCVA) and the following spectral-domain optical coherence tomography (SD-OCT) subfoveal parameters: central macular thickness (CMT), outer nuclear layer, external limiting membrane, ellipsoid zone, interdigitation zone, choroidal thickness and subretinal fluid (SRF).
Results
F group comprised 33 eyes (47.1%) and E group comprised 37 eyes (52.9%). Both groups showed an improvement of BCVA after HD-PDT with no significant differences in final BCVA (p=0.41). CMT and SRF showed a significant improvement after HD-PDT in both groups, but the rate of disruption of the external retinal layers remained stable. During follow-up, SD-OCT parameters and the rate of anatomical success showed no significant differences regarding the treatment location. No major sequelae were noticed.
Conlusions
Foveal and extrafoveal applications of HD-PDT for cCSC showed comparable efficacy and safety.
Financial Disclosure
This research received no financial support. The authors declare no financial, institutional nor commercial interests related to the research.
Comments
-